Morgan Stanley Aligos Therapeutics, Inc. Transaction History

Morgan Stanley

  • $1.35 Trillion
  • Q3 2024

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Aug 16, 2024
BUY
$0.64 - $1.13 $832 - $1,468
1,300 Added 65.0%
3,300 $3,000
Q1 2024

May 15, 2024
BUY
$0.64 - $1.13 $832 - $1,468
1,300 Added 65.0%
3,300 $3,000
Q4 2023

Aug 16, 2024
SELL
$0.56 - $0.8 $728 - $1,040
-1,300 Reduced 39.39%
2,000 $1,000
Q3 2023

Nov 15, 2023
SELL
$0.71 - $1.06 $710 - $1,060
-1,000 Reduced 33.33%
2,000 $1,000
Q2 2023

Aug 14, 2023
SELL
$0.89 - $1.36 $115,454 - $176,424
-129,724 Reduced 97.74%
3,000 $2,000
Q1 2023

May 15, 2023
BUY
$0.87 - $2.11 $113,422 - $275,082
130,371 Added 5540.63%
132,724 $115,000
Q4 2022

Feb 14, 2023
SELL
$0.89 - $28.0 $7,056 - $222,012
-7,929 Reduced 77.12%
2,353 $2,000
Q3 2022

Nov 14, 2022
SELL
$1.06 - $27.5 $44,870 - $1.16 Million
-42,331 Reduced 80.46%
10,282 $11,000
Q2 2022

Oct 27, 2022
SELL
$1.04 - $2.14 $28,596 - $58,843
-27,497 Reduced 34.32%
52,613 $64,000
Q2 2022

Aug 15, 2022
SELL
$1.04 - $2.14 $28,596 - $58,843
-27,497 Reduced 34.32%
52,613 $64,000
Q1 2022

Oct 27, 2022
BUY
$2.08 - $12.2 $57,193 - $335,463
27,497 Added 52.26%
80,110 $171,000
Q1 2022

May 13, 2022
BUY
$2.08 - $12.2 $59,155 - $346,968
28,440 Added 55.04%
80,110 $171,000
Q4 2021

Feb 14, 2022
SELL
$11.48 - $17.69 $4.8 Million - $7.39 Million
-417,734 Reduced 88.99%
51,670 $613,000
Q3 2021

Nov 15, 2021
BUY
$14.57 - $17.72 $6.84 Million - $8.32 Million
469,404 New
469,404 $7.28 Million

Others Institutions Holding ALGS

# of Institutions
3
Shares Held
253K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $751M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email